Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 42(4); 2018 > Article
Letter
Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)
Jin Hwa Kimorcid
Diabetes & Metabolism Journal 2018;42(4):348-349.
DOI: https://doi.org/10.4093/dmj.2018.0135
Published online: August 21, 2018
  • 3,741 Views
  • 42 Download
  • 1 Crossref
  • 3 Scopus

Department of Endocrinology and Metabolism, Chosun University Hospital, Chosun University College of Medicine, Gwangju, Korea.

corresp_icon Corresponding author: Jin Hwa Kim. Department of Endocrinology and Metabolism, Chosun University Hospital, Chosun University College of Medicine, 365 Pilmun-daero, Dong-gu, Gwangju 61453, Korea. endocrine@chosun.ac.kr

Copyright © 2018 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
Early identification and optimal management of acute coronary syndrome (ACS) are important for improvement of prognosis and reduction of mortality [1]. Easy and non-invasive diagnostic and prognostic methods of ACS may allow physicians to initiate earlier precision strategies to prevent adverse outcome. Several biomarkers including troponin I, N-terminal pro-B type natriuretic peptide, creatinine kinase, and high-sensitivity C-reactive protein are available [23].
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces the uptake of low density lipoprotein (LDL) cholesterol by increasing the endosomal and lysosomal degradation of LDL receptor, accompanied by an increase in circulating LDL [45]. PCSK9 has been considered as a promising target for lipid-lowering therapy [6]. Recently, several studies showed the new role of PCSK9 in the pathogenesis of ACS and suggested a potential parameter for decision-making in ACS [789].
In this article entitled "Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome," Bae et al. [10] evaluated whether a high level of serum PCSK9 is associated with a high risk and severity of ACS. They showed that serum PCSK9 levels were positively associated with the proportion of patients with coronary angiography lesions after adjustment for multiple variables, suggesting that PCSK9 is a potential biomarker of the severity of coronary artery disease. The authors have clearly showed their results in this manuscript, and this approach is quite valuable and helpful to establish a method for early identification and individual strategies of ACS.
However, these results may not be generalizable to all patients because only male participants were enrolled. I hope for a large multicentre prospective cohort study including both genders, especially considering the menopausal state. I also expect to extend the study to see whether there is an association between the level of PCSK9 and prognosis such as recurrence rate and mortality. Lastly, it would have more valuable if they could compare PCSK9 and other biomarkers of ACS, as the authors mentioned.

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

  • 1. Fanaroff AC, Rymer JA, Goldstein SA, Simel DL, Newby LK. Does this patient with chest pain have acute coronary syndrome? The rational clinical examination systematic review? JAMA 2015;314:1955-1965. ArticlePubMed
  • 2. Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, Chapman AR, Langdon T, Sandeman D, Vaswani A, Strachan FE, Ferry A, Stirzaker AG, Reid A, Gray AJ, Collinson PO, McAllister DA, Apple FS, Newby DE, Mills NL. High-STEACS investigators. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet 2015;386:2481-2488. ArticlePubMedPMC
  • 3. Zdravkovic V, Mladenovic V, Colic M, Bankovic D, Lazic Z, Petrovic M, Simic I, Knezevic S, Pantovic S, Djukic A, Zdravkovic N. NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes. Kardiol Pol 2013;71:472-479. ArticlePubMed
  • 4. Seidah NG, Awan Z, Chretien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res 2014;114:1022-1036. ArticlePubMed
  • 5. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res 2012;53:2515-2524. ArticlePubMedPMC
  • 6. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013;35:1082-1098. ArticlePubMed
  • 7. Gencer B, Montecucco F, Nanchen D, Carbone F, Klingenberg R, Vuilleumier N, Aghlmandi S, Heg D, Raber L, Auer Ra, Juni P, Windecker S, Luscher TF, Matter CM, Rodondi N, Mach F. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J 2016;37:546-553. ArticlePubMed
  • 8. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-1499. ArticlePubMed
  • 9. Liberale L, Carbone F, Bertolotto M, Bonaventura A, Vecchie A, Mach F, Burger F, Pende A, Spinella G, Pane B, Camici GG, Palombo D, Dallegri F, Montecucco F. Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. Int J Cardiol 2018;263:138-141. ArticlePubMed
  • 10. Bae KH, Kim SW, Choi YK, Seo JB, Kim N, Kim CY, Lee WK, Lee S, Kim JG, Lee IK, Lee JH, Park KG. Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome. Diabetes Metab J 2018;42:207-214. ArticlePubMedPMCPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • PCSK9 gene participates in the development of primary dyslipidemias
      D Matías-Pérez, AD Pérez-Santiago, MA Sánchez Medina, JJ Alpuche Osorno, IA García-Montalvo
      Balkan Journal of Medical Genetics.2021; 24(1): 5.     CrossRef

    • PubReader PubReader
    • Cite this Article
      Cite this Article
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)
      Diabetes Metab J. 2018;42(4):348-349.   Published online August 21, 2018
      Close
    • XML DownloadXML Download
    Related articles
    Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)
    Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)
    Kim JH. Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14). Diabetes Metab J. 2018;42(4):348-349.
    DOI: https://doi.org/10.4093/dmj.2018.0135.

    Diabetes Metab J : Diabetes & Metabolism Journal
    Close layer
    TOP